Anavex Life Sciences Corp.
Cash Flow Statement
| Line Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Operating Activities | ||||||||
| Net Income | $-46.4M | $-43.0M | $-47.5M | $-48.0M | $-37.9M | $-26.3M | $-26.3M | $-17.3M |
| Depreciation & Amortization | — | — | — | — | — | — | — | — |
| Depreciation | — | — | — | — | — | — | — | — |
| Amortization | — | — | — | — | — | — | — | — |
| Stock-Based Compensation | $11.5M | $9.4M | $16.4M | $18.4M | $8.2M | $4.9M | $6.4M | $5.5M |
| Net Cash from Operating Activities | $-39.0M | $-30.8M | $-27.8M | $-24.2M | $-30.4M | $-21.3M | $-18.5M | $-12.6M |
| Investing Activities | ||||||||
| Capital Expenditures | — | — | — | — | — | — | — | — |
| Business Acquisitions | — | — | — | — | — | — | — | — |
| Net Cash from Investing Activities | — | — | — | — | — | — | — | — |
| Financing Activities | ||||||||
| Dividends Paid | — | — | — | — | — | — | — | — |
| Stock Repurchases | — | — | — | — | — | — | — | — |
| Net Cash from Financing Activities | $9.4M | $12.0M | $29.7M | $21.3M | $153.2M | $28.4M | $17.8M | $8.1M |
| Net Change in Cash | — | — | — | — | — | $7.1M | $-745.0K | — |
| Free Cash Flow | — | — | — | — | — | — | — | — |